For 2020, the International Psoriasis Council is pleased to announce the availability of five year-long fellowships through the IPC International Fellowship Program.
Meet the 2018 IPC International Fellows.
Meet the 2019 IPC International Fellows.
The International Fellowship Program aims to increase the number and ability of clinicians and scientists focused on researching and treating psoriasis. Beginning in January 2020, fellows will be matched with, and observe, IPC Board Members and Councilors in their clinics and laboratories to get real world practice in researching, diagnosing, developing treatment plans and monitoring treatment regiments for psoriasis patients. In addition, the program will provide an opportunity for IPC Fellows to develop on-going relationships with key opinion leaders by participating in IPC programs and activities throughout the one-year Fellowship period.
Fellowships are available to early career dermatologists in training or junior faculty who have completed their training within the last five years and are interested in improving their abilities to treat and manage psoriasis patients, gain exposure to international key opinion leaders and develop leadership skills among peers.
Complete the online application, uploading the following in PDF format:
The application must be submitted online with all supporting documents by 11:59 pm PST on Monday, September 30th. Late or incomplete applications will not be considered.
Sites are available in Latin America, North America, Europe and Asia. IPC will provide the final site list to awarded fellows who will then select their top three choices. Final matches will be made by the Steering Committee, comprised of IPC Board Members and Councilors. Learn more about the program
For questions about the IPC International Fellowship Program, please send an email to Fellowship@psoriasiscouncil.org.
IPC Psoriasis Review Newsletter IPC's bi-annual review of the latest manuscripts in the field of psoriasis. Read the latest issue
IPC's bi-annual review of the latest manuscripts in the field of psoriasis.
Psoriasis News Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis8/20/2019 10:08:00 AMEli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease8/6/2019 11:36:00 AMCelgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Updated Disease Classification System Adopted by the World Health Organization8/1/2019 7:19:00 AMOn 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022. FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)8/1/2019 7:09:00 AMSamsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below. More News